论文部分内容阅读
目的观察头孢泊肟酯治疗急性细菌感染的安全性、有效性。方法115例细菌感染性疾病病人随机分为2组:对照组55例,男性24例,女性31例,年龄(43±s 13)岁;试验组60例,男性35例,女性25例,年龄(42±13)岁。对照组予头孢克肟200 mg,po,bid;试验组予头孢泊肟酯100 mg,po, bid,疗程均为7～12 d。观察2组临床疗效、细菌学疗效及不良反应情况。结果试验组和对照组临床痊愈率分别为73%和69%,有效率分别为93%和91%,细菌清除率分别为98%和94%,均无显著差异(P>0.05)。2组均未出现严重不良反应,不良反应率分别为7%和9%,无显著差异(P>0.05)。结论头孢泊肟酯治疗急性细菌感染安全、有效。
Objective To observe the safety and efficacy of cefpodoxime proxetil in the treatment of acute bacterial infections. Methods One hundred and fifteen patients with bacterial infectious disease were randomly divided into two groups: control group (55 cases), male 24 cases and female 31 cases (43 ± s 13) years old. The experimental group consisted of 60 cases, 35 males and 25 females, (42 ± 13) years old. The control group was given cefixime 200 mg, po, bid. The experimental group was treated with cefpodoxime proxetil 100 mg, po, bid for 7-12 days. The clinical efficacy, bacteriological efficacy and adverse reactions of the two groups were observed. Results The clinical cure rates were 73% and 69% in the test group and the control group respectively. The effective rates were 93% and 91%, respectively. The bacterial clearance rate was 98% and 94% respectively, with no significant difference (P> 0.05). No serious adverse reactions occurred in both groups, with adverse reactions of 7% and 9%, respectively, with no significant difference (P> 0.05). Conclusion Cefpodoxime proxetil is safe and effective in the treatment of acute bacterial infections.